.Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XX02_IbritumomabTiuxetan90y.IbritumomabTiuxetan90y .Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XX02_IbritumomabTiuxetan90y.IbritumomabTiuxetan90y| name: | IbritumomabTiuxetan90y | |
| ATC code: | V10XX02 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 15 | mg |
| volume of distribution: | 3.5 | L |
| clearance: | 20 | mL/h/kg |
| other parameters in model implementation | ||
Ibritumomab tiuxetan (90Y) is a radiolabeled monoclonal antibody targeting the CD20 antigen on B cells. It is used as a radioimmunotherapy for treatment of certain types of non-Hodgkin's lymphoma, including relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Its use is currently limited and it is not widely approved or available in many countries.
Pharmacokinetic parameters are primarily derived from adult cancer patients with non-Hodgkin's lymphoma, both sexes, aged 18-80, without major renal or hepatic insufficiency.